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Emerging pathogens could pose a substantial threat to
recipients of therapeutic coagulation-factor concentrates
(CFC), as shown by the devastating effect of HIV on
patients who received these agents. The safety of CFC
has improved greatly since their introduction, and the
risk of infectious diseases caused by plasma-derived
preparations is now very small. However, everyone
concerned with haemophilia, including various
scientific and medical advisory committees, agrees that
vigilance must be maintained to ensure that new and
unpredictable emerging blood-borne pathogens will not
again compromise the safety of CFC in the future.1–3 The
risk of transmission of infectious agents by a fresh blood
component is very different from that for CFC because
there might not be an effective pathogen inactivation or
removal step in the preparation process, and the dose of
infectious agent could be much higher than in CFC. The
special danger of contamination of CFC with pathogens
is that a single batch could be used to treat, and possibly
infect, hundreds of patients, as happened with HIV. The
pathogens discussed in this review are all potentially
transmissible by fresh blood products. The susceptibility
to individual pathogens in fresh blood products in a
particular community will depend on the local
epidemiology of the infectious agent. By contrast, CFC
commonly cross continents from site of plasma
collection and fractionation to use in recipients in a
community with little experience of the agent. This
review focuses on the potential for emerging risks of
infectious agents in CFC because an essential public-
health objective is to prevent epidemics of serious viral
infections in patients with haemophilia and others who
depend exclusively on CFC for their well-being.
The review is a summary of an interdisciplinary forum
of clinicians who treat haemophilia, infectious-disease
specialists, and epidemiologists that was convened at
Washington University School of Medicine in St Louis,
MO, USA, in June, 2004, to discuss infectious-disease
risk management in patients with haemophilia. The
forum had the following objectives: to review emerging
blood-borne pathogens and their potential effects on
therapeutic CFC; to discuss clinical issues related to viral
infections in patients with haemophilia; and to review
the safety of CFC in terms of transfusion-transmissible
infections.
Emergence of new human pathogens
The National Academy of Sciences defines an emerging
infection as one that is newly identified, re-emerging, or
drug resistant, with an incidence in people that has
increased within the previous two decades or is
threatening to increase in the near future.4 The first step
of emergence, known as introduction, occurs when a
previously unknown pathogen comes into contact with a
new host population, or when an established pathogen
changes its normal interaction pattern with its host
population in some crucial way to increase in
prevalence. In the second step, known as adaptation, the
emerging agent becomes established and disseminates
within the host population. The factors that contribute to
this process are complex; they include microbial
adaptation, advances in technology and industry,
international travel and commerce, the breakdown of
public-health measures, economic development and
increased land use, changes in human demographics
and behaviour, and war and famine.4
The introduction of a new pathogen into a previously
unexposed population typically occurs by interspecies, or
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As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses,
and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates
(CFC) are now judged safe in terms of many known infectious agents, including hepatitis B and C viruses, HIV, and
human T-cell lymphotropic virus. However, emerging pathogens could pose future threats, particularly those with
blood-borne stages that are resistant to viral-inactivation steps in the manufacturing process, such as non-lipid-
coated viruses. As outlined in this Review, better understanding of infectious diseases allows challenges from newly
described agents of potential concern in the future to be anticipated, but the processes of zoonotic transmission and
genetic selection or modification ensure that plasma-derived products will continue to be subject to infectious
concerns. Manufacturers of plasma-derived CFC have addressed the issue of emerging infectious agents by
developing recombinant products that limit the need for human plasma during production. Such recombinant
products have extended the safety profile of their predecessors by ensuring that all reagents used for cell culture,
purification steps, and stabilisation and storage buffers are completely independent of human plasma.
Search strategy and selection criteria
The references were selected by the authors from their
knowledge of published work.
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zoonotic, transmission. For example, genetic analyses
have suggested that HIV infection was transmitted to
human beings from a common subspecies of
chimpanzee (Pan troglodytes troglodytes).5 Another well-
publicised example of zoonotic transmission is severe
acute respiratory syndrome, caused by the transmission
of a new coronavirus to people, initially in southern
China and probably from small mammals, which are the
natural hosts of the severe-acute-respiratory-syndrome
coronavirus.6 After the virus first appeared in human
beings, there was an explosive short epidemic. Since
clinical symptoms preceded the peak of transmission of
this virus, outbreaks were restricted by quarantine
measures in China, Canada, and other countries. Many
epidemiologists predict similar types of outbreaks in the
future with emerging viruses.
A less widely known case of zoonotic transmission is
of Nipah virus, a henipavirus that causes potentially
lethal encephalitis. The natural host is the flying fox
(fruit bat); cross-species transmission of the virus to
animals occurred in southeast Asia where farmers
inhabited areas that had been cleared of forests,
inadvertently exposing their livestock to flying-fox
habitats.7,8 In the late 1990s, there were several outbreaks
of Nipah-virus infection in pigs, with subsequent
transmission of the virus to human beings. In Malaysia,
of 265 people infected during an outbreak of Nipah-virus
infection, 105 died, a mortality rate of 40%.9 Two other
outbreaks of Nipah-virus infection have since occurred
in Bangladesh.7,8 The mortality rate among infected
individuals approached 70% in the Bangladeshi
outbreaks, and in contrast to the Malaysian outbreaks,
the virus might have been transmitted from one person
to another. Hendra virus, a type of henipavirus, causes
disease in horses and was reported to be transmitted via
exposure to secretions from an infected racehorse to its
trainer. The transmission vector remains unknown but
could be an arthropod.10
Any new viral pathogen poised to infect human beings
must breach the natural barriers to zoonotic
transmission that exist at the levels of cellular entry and
viral expression. New emergent viruses might therefore
have to acquire genetic mutations before active
propagation within people is possible. Some RNA
viruses have mutation rates as high as one nucleotide
per 10 000 copied and therefore could be especially likely
candidates for zoonotic transmission.11 However, the
evolution of a potentially large number of adaptive
mutations that enable productive replication and
efficient continuing transmission in a new host is rare,
which might help to explain the low frequency of
emerging agents. However, when an emerging
pathogen does succeed in adapting to a new host
species, the outcome can have a worldwide effect. New
pathogens are also more likely to emerge in conjunction
with opportunistic infections in highly immunosup-
pressed individuals, such as those with congenital
immune defects, cancer, or AIDS.12 Immunosuppres-
sion, especially in xenotransplantation settings, might
enable a poorly adapted virus to replicate and adapt to
human beings and act as a bridge to subsequent
infection of the healthy population.13,14
These issues apply to infectious agents entering a new
host population, but any pre-existing aetiological agent for
which the incidence has increased within the previous
two decades is also defined as an emerging pathogen. In
many cases, an increase in incidence reflects a change in
the interaction between host and vector, such as that
caused by extraordinary changes in ecosystems.15 For
example, Rift Valley fever was the ultimate cause of a
cumulative 200 000 deaths after construction of the
Aswan Dam on the River Nile in Egypt in the 1960s
created conditions in which the arthropod vector
flourished.16 Guanarito arenavirus emerged in Venezuela
after forest clearing disrupted the local ecology.17 This viral
pathogen can be transmitted from rats to human beings,
in whom it causes haemorrhagic fever and can pose a
threat to the blood supply. As more people congregate
within mega-cities, especially those of less developed
countries with less advanced hygiene systems, more
emerging infectious agents that arise by disruption of
ecosystems can be expected.
After introduction and adaptation, the final step in
pathogen emergence is the dissemination of the
emerging infectious agent within the host population.
This step can occur with an explosive short outbreak,
such as that observed for the Ebola virus or the
coronavirus associated with severe acute respiratory
syndrome. Alternatively, the agent can propagate and
spread via a slower and more insidious mechanism,
such as that observed with HIV.
Potential threats to blood and blood products
Many infectious agents transmissible by blood
transfusion are characterised by a long-lasting and silent
carrier state in which the pathogen circulates in the
blood without causing noticeable symptoms.18 Blood
Panel: Viruses
CPV Canine parvovirus
FPLV Feline panleucopenia virus
HBV Hepatitis B virus
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HTLV Human T-cell lymphotropic virus
JEV Japanese encephalitis virus
PCV Porcine circovirus
SLE St Louis encephalitis virus
TTMV Torque-tenominivirus
TTV Torque-tenovirus
WNV West Nile virus
YFV Yellow-fever virus
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collected during this phase can be highly infective, even
though the donor has no symptoms. Agents that meet
these criteria include hepatitis B and C viruses (HBV
and HCV), HIV, human T-cell lymphotropic viruses
(HTLV) I and II, and West Nile virus (WNV).19 Because
there is routine screening for these agents, blood and
blood products are generally thought to be safe from
these pathogens. However, many other viruses, for
which donated blood is not routinely screened, are
known to produce a viraemic phase in the infected
individual. (Viruses for which we use an abbreviated
name in this review are listed in the panel.)
Lipid-enveloped viruses
Flaviviruses, which are small, lipid-enveloped, positive-
stranded RNA viruses, are a subfamily of arthropod-
borne viruses (arboviruses) that cycle between insect and
vertebrate hosts. At least 40 species are associated with
human disease, including WNV, dengue virus, St Louis
encephalitis virus (SLE), yellow-fever virus (YFV), and
Japanese encephalitis virus (JEV).20,21 Human beings are
the primary host for dengue virus and YFV only.
Arboviruses have a vast global distribution and show
intriguing emergence patterns based on ecological
changes (figure 1).22 Because flaviviruses are widespread
and persistent in insect and animal populations and are
so far resistant to existing treatments, they pose a
potential threat to the blood supply.
West Nile virus
This flavivirus is spread by mosquito vectors. The most
important clinical phenotype of non-lethal infection is
meningoencephalitis.23 The virus first emerged during a
1999 outbreak in New York City, resulting in
62 confirmed cases and 22 deaths.24–26 During 2000 and
2001, similar numbers of human cases were noted in the
eastern USA, and evidence of WNV found in birds, farm
animals, and mosquito pools showed that the virus had
spread over the whole eastern coast and had begun to
spread westward. In 2003, the US Centers for Disease
Control and Prevention reported 9862 cases of WNV
infection in 46 states and 264 associated deaths. The
numbers were smaller in 2004, with 2470 reported cases
in 41 states and 88 associated deaths. Infections have now
been recorded in some parts of Canada and Mexico.
Currently, 2% to 3% of people in certain areas of the USA
are seropositive for WNV. The estimated risk, for
example, of transmission of the virus through transfusion
during the 1999 epidemic in New York was about
2·0 viraemic donations per 10 000 donors in the borough
of Queens.27 The risk varied greatly with time and location
during 2002, reaching as high as 1·5 in 1000 donations.18
Of the 2·5 million blood donations screened for WNV
from June to December, 2003, 0·05% were positive at first
screen, and 0·02% were confirmed. Interventions to
block transmission of WNV are hampered by the fact that
80% of cases of infection are subclinical or asymptomatic.
Since WNV is readily inactivated by low pH, high
temperature, and detergents, it is of less concern with
plasma-protein-derived CFC, for which these treatments
are typically used during manufacturing.
Dengue fever and dengue haemorrhagic fever
Dengue virus is the most common arthropod-
transmitted virus in the world and is an important issue
worldwide for the blood supply.28 Each year, there are
25 million to 100 million cases of dengue fever and
250 000 cases of dengue haemorrhagic fever throughout
the world.29 Dengue haemorrhagic fever or dengue
shock syndrome has a mortality rate of 10–40%,
depending on the degree of access to high-quality
tertiary-care facilities. Between 1980 and 1999, the
number of cases of dengue virus in the Americas
increased by 50 times (figure 2).30 The primary mosquito
vector for dengue virus, Aedes aegypti, was almost
eradicated from the USA after the DDT spraying
campaigns in the late 1950s but the population is now
recovering.31 By comparison, in Brazil there is an
epidemic of dengue fever and dengue haemorrhagic
fever, with an estimated 500 000 to 1 000 000 cases per
year. Other epidemics are occurring in Central America,
southeast Asia, and parts of Africa and Oceania.
Worldwide, an estimated 2·5 billion people are at risk.
The infection has a viraemic phase that lasts 3–5 days,
and most cases remain subclinical. Since no screening
tests are in place, dengue virus might be expected to
pose a future concern for the blood supply.
JEV
This virus is another important arbovirus threatening
global blood supplies.32–34 It causes severe encephalitis,
and the mortality among patients admitted to hospital is
about 33%, with many survivors having long-term
neurological sequelae. The heaviest concentrations of
infections are in southeast Asia and the Indian
subcontinent. 20 000–50 000 cases are reported every
year in China alone.
West Nile encephalitis
St Louis encephalitis
Japanese encephalitis
Murray Valley encephalitis
Combination of West Nile and St Louis encephalitis
Figure 1: Approximate global distribution of medically important viruses in
the Japanese encephalitis serogroup of flaviviruses22
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Non-lipid-enveloped viruses
Viruses without lipid envelopes tend to be less susceptible
than lipid-enveloped viruses to inactivation methods
because they are typically smaller in size and are likely to
have greater resistance to heat, irradiation, and solvent
detergent treatment. Emerging non-lipid-enveloped
viruses could therefore pose the greatest threat to plasma-
derived CFC, particularly in light of the recent outbreaks
of infections with enteroviruses.35
Enteroviruses
These small non-lipid-enveloped viruses form a separate
genus within the picornavirus family. More than
70 serotypes have been isolated from people, including
polioviruses, coxsackieviruses, enterocytopathic human
orphan viruses, and enteroviruses 68–71. The normal site
of replication for these viruses is the gastrointestinal tract;
infection is subclinical or results in a mild disorder in
many cases. However, some of these viruses can spread
through the blood to other parts of the body, including the
central nervous system. The resulting diseases can be
severe, partly depending on the specific enterovirus
serotype. Enteroviruses that undergo viraemic phases in
their life cycle and are associated with substantial
morbidity (eg, enteroviruses 70 and 71) could be
particular threats to blood products.36–40 Enterovirus 70
was the causative agent of epidemics of acute
haemorrhagic conjunctivitis in Africa, Asia, India, and
Europe between 1969 and 1974. Enterovirus 71 seems to
be highly pathogenic and neurovirulent and has been
associated with epidemics (eg, in Taiwan, Japan, and
Australia) of various acute diseases, including aseptic
meningitis, encephalitis, paralytic poliomyelitis-like
disease, hand-foot-and-mouth disease, herpangina, non-
specific febrile illness, upper-respiratory-tract infection,
enteritis, and viral exanthema.36–38 Enterovirus infections
can have a transient viraemic phase that precedes
symptoms. This feature, in combination with their
resistance to inactivation, makes them a potential threat to
the blood and CFC supplies. In a study in Scotland,
0·024% of blood donations showed evidence of
enterovirus viraemia.41 This proportion predicts about
1000 enterovirus-contaminated transfusions per year in
the UK. A wide range of viral loads (figure 3) and
enterovirus serotypes were detected, including entero-
virus 71, coxsackieviruses A2, A5, A10, A16, B2, B3, B4,
and B5, and echoviruses 11, 13, 18, and 30. In the light of
the numbers of potential infected donations, initiation of
screening methods for enteroviruses might be prudent to
exclude the possibility of blood-transfusion-associated
transmission of potentially pathogenic variants such as
enteroviruses 70 and 71.
Circoviruses
These viruses are the smallest known mammalian non-
lipid-enveloped viruses (18–28 nm) and are distributed
ubiquitously among human beings and other mammals.42
Human circoviruses include torque-tenovirus (TTV) and
torque-tenominivirus (TTMV), two related viruses with
highly divergent sequences. Each has a vast number of
distinct genotypes. Infected people seem to be viraemic
with a wide range of genotypes of both viruses, and viral
loads are constantly high. Importantly for blood products,
these extremely small and stable non-lipid-enveloped
viruses cannot be removed easily by nanofiltration and as
with other circoviruses important in veterinary medicine,
such as porcine circovirus (PCV), they are likely to be
highly resistant to heat and other viral inactivation
protocols used in manufacture of blood products. There
are no known human diseases associated with
circoviruses, but some features suggest that caution is
warranted. These viruses have been associated with
clinical disease in other species; infection with PCV2 is
the most commercially important disease in pigs today,
leading to multisystemic wasting syndrome.43 The virus is
the cause of 15% of deaths in pigs, and it has already
jumped species to cattle and sheep. Chicken anaemia
virus, an avian circovirus, has been transmitted through
contaminated manufactured livestock feed, a further
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indication of the resistance to inactivation of these
viruses. In human beings, transmission of circoviruses to
neonates can be associated with upper-respiratory-tract
infection.44 Since these viruses might maintain their
continuously viraemic but asymptomatic state in human
beings through some immunosuppressive function, there
is a theoretical concern that they might also suppress the
immune response to other infectious agents.
Parvoviruses
Interspecies jumping is one of the primary routes by
which new emerging pathogens enter the human
population. The parvovirus feline panleucopenia virus
(FPLV) might therefore constitute a future threat to
people because of its ability to cross mammalian barriers.
It is a small non-lipid-enveloped virus that typically
infects cats, mink, raccoons, Arctic foxes, and raccoon
dogs. In 1978, a new pathogenic variant emerged in dogs
and became known as canine parvovirus (CPV),45 which
causes hyperthermia, vomiting, diarrhoea, leucopenia,
dyspnoea, myocarditis, pneumonitis, and in some cases,
virus-induced encephalitis.46,47 FPLV took about a decade
to assume its new host range.48,49 One of the first changes
that differentiated CPV from FPLV and other animal
viruses was in the haemagglutinin molecule. Since then,
strains of CPV have undergone a series of changes,
presumably in response to evolutionary selection, which
resulted in the global distribution of new variants.48 New
antigenic variants (CPV2 types, including 2a, followed by
2b then 2c) have been isolated from cats and dogs in Japan
and Brazil, which suggests that interspecies transmission,
and presumably genetic conversion, continues.50–52 Host
adaptation of CPV in canines suggests the possibility of
similar cross-species transmission, followed by adaptation
in human beings.52 This potential development could be
accelerated by the close contact between dogs and people
throughout the world. Because they are small, resistant,
non-lipid-enveloped viruses, such emerging parvoviruses
could pose a substantial future threat to blood and blood
products.
Polyomaviruses
Polyomaviruses, a genus of the larger papovavirus family,
are small non-lipid-enveloped viruses that might also pose
a future risk to blood products. Two viruses, both of which
were isolated in 1971, are of particular interest. JC virus
was first isolated from the brain of a patient with Hodgkin’s
disease who subsequently developed progressive multifocal
leucoencephalopathy. BK virus was first isolated from a
susceptible immunosuppressed patient who had recently
received a kidney transplant. The main site in the body
found to harbour these viruses is the kidney. Lymphoid
tissues, including bone marrow and spleen, have also been
identified as sites of potential viral latency.53–55 Both viruses
have also been found in brain tumours.56
BK virus causes mild upper-respiratory-tract symptoms,
occasional pyrexia, and transient cystitis in immuno-
competent individuals. In immunocompromised
patients, the infection is predominantly associated with
diseases of the urogenital tract, particularly haemorrhagic
cystitis.54 Nephropathy associated with BK virus is
emerging as an important cause of renal dysfunction and
loss of transplanted kidneys; the frequency of infection
with BK virus in transplant recipients is 5%.57,58 Perhaps of
greater concern, nucleic-acid sequences from the virus
have been reported to persist in mononuclear cells of
healthy blood donors. Thus, of 231 individuals tested in a
study in two different centres, 29% were positive for BK-
virus sequences.54
Clinical infection with JC virus is generally found in
association with long-term immunosuppression and
other chronic diseases, including AIDS, lymphoprolif-
erative diseases such as Hodgkin’s disease and chronic
lymphocytic leukaemia, sarcoidosis, tuberculosis, and
systemic lupus erythematosus. JC virus causes chronic
meningoencephalitis and is associated with progressive
multifocal leucoencephalopathy, a fatal demyelinating
disease of the central nervous system. Typically, the
course of progressive multifocal leucoencephalopathy is
gradual, with initial impairment of cognitive function,
speech, vision, and movement. As it progresses, the
pathology accelerates, and patients develop more severe
disabilities, including dementia, paralysis, blindness, then
coma, followed by death. The frequency of progressive
multifocal leucoencephalopathy increased with the AIDS
pandemic, but now, with effective antiretroviral therapy,
HIV-infected patients rarely develop this disorder.51,52
Shedding of JC virus (and BK virus) in urine is
significantly more common in HIV-infected patients than
in non-HIV-infected individuals.59 Progressive multifocal
leucoencephalopathy is rare in children and young adults
and is more common in people in their 50s and 60s; this
feature suggests that reactivation of latent virus, and not
primary infection, is the cause of viral disease.
Prions
Prions are self-replicating proteins implicated in
transmissible spongiform encephalopathies in people and
animals. The prion protein in its physiological form, PrPc,
is a normal membrane constituent. Its function is
uncertain, although it might be involved in synaptic
transmission or copper metabolism. The protein
can undergo conformational change to a pathological
form in which it is protease-resistant (PrPres) and it might
also have altered glycosylation. This conformational
change increases the protein’s ability to aggregate. This
form is the agent that causes transmissible spongiform
encephalopathies.
The most worrying manifestation of transmissible
spongiform encephalopathies for people is variant
Creutzfeldt-Jakob disease, which was first recognised in
1996.60 The disease is caused by an infectious prion
similar to that which causes bovine spongiform
encephalopathy and is transmitted by consumption of
Review
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contaminated tissue from bovine sources. The prion that
causes variant Creutzfeldt-Jakob disease is found in
lymphoid tissue, in contrast to cases of the classic disease,
and it therefore presents a potential risk of infection
through blood and plasma-derived blood products.61
Several studies have shown that prions can be
transmitted through blood. In one study, 68% of PrPc
quantified in normal blood samples was in the plasma
compartment, which highlights the potential for similar
distributions of infectious prion. Leucocyte depletion
alone might be insufficient to prevent transmission of
PrPres (figure 4).62 Furthermore, sheep experimentally
infected with the infectious prion associated with bovine
spongiform encephalopathy or scrapie transmitted the
encephalopathies to unexposed sheep at a rate of 10–20%
after whole-blood donations. Finally, two human cases of
probable transmission of the prion associated with variant
Creutzfeldt-Jakob disease by blood from donors who
subsequently developed the disorder have been reported.
In the first case, the recipient received a transfusion in
1996, developed a neurological disorder in 2002, and died
13 months after the onset of symptoms. At autopsy,
characteristic spongiform change was seen in the brain.63
The second patient died 5 years after a blood transfusion
from a donor who subsequently developed variant
Creutzfeldt-Jakob disease. At autopsy, however, PrPres was
found in the spleen and cervical lymph nodes, but there
was no spongiform histological change or PrPres in the
brain.64
At present, variant Creutzfeldt-Jakob disease from
infected blood donors poses mainly a theoretical risk to
plasma-derived coagulation factors.65 The risk could be
less than that associated with fresh blood components
because the pathogenic prion will be diluted in the
starting plasma pool and because it is partly excluded by
the differential protein fractionation process from the
final CFC.66 More highly purified CFC would probably
carry a lower risk of prion transmission. However,
without a reliable diagnostic test for prions, some concern
about these agents will remain. In September, 2004,
serious concerns prompted the UK Departments of
Health to issue letters to 6000 recipients of products
manufactured from UK plasma, warning them that there
was a possibility of transmission of variant Creutzfeldt-
Jakob disease.
Public-health response
Regulatory bodies track adverse outcomes from the use of
blood products, and public-health agencies track
infectious disease, but surveillance for infectious agents
in the blood supply is at an early stage and is not always
done efficiently. Effective surveillance of blood products
requires a coordinated effort by regulatory bodies,
manufacturers, and treaters. Regulatory bodies must
mandate effective postmarketing surveillance. Manufac-
turers must use their global reach to identify rare adverse
events, and treaters must report adverse events as in the
system established by UK Haemophilia Doctors’
Organisation. Machine-readable labels such as those with
bar codes, electronic health-record databases that track
clinical outcomes, and consented tissue archives such as
those of the US Centers for Disease Control and
Prevention and the Blood Borne Pathogens Surveillance
Project of the Association of Hemophilia Centre Directors
of Canada are key tools for effective and efficient
surveillance.67 Table 1 lists some of these organisations.
Current clinical topics: viral disease in patients
with haemophilia
Individuals with haemophilia and their physicians are
particularly concerned about emerging blood-borne
infectious diseases because the patients are continually
exposed to blood and blood-derived products. The
problems associated with HIV provide an example of the
dangers faced by these people. HIV contamination of the
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Figure 4: Quantification of PrPc protein in fractionated human blood62
Region and organisation Website
UK
UK Haemophilia Alliance http://www.haemophiliaalliance.org.uk
UK Haemophilia Society http://www.haemophilia.org.uk
UK Haemophilia Centre Doctors’ Organisation http://www.ukhcdo.org
National Creutzfeldt-Jakob Disease Surveillance http://www.cjd.ed.ac.uk
Unit
Canada
Association of Hemophilia Clinic Directors of http://www.ahcdc.ca/
Canada
Blood-Borne Pathogens Surveillance Project http://www.ahcdc.ca/bbpsp
Canadian Hemophilia Society http://www.hemophilia.ca/en/1.1.1.php
Blood-Borne Pathogen Surveillance http://www.hc-sc.gc.ca/pphb-dgspsp/hcai-iamss/bpp-pts/sys_e.html
Network
USA
US National Hemophilia Foundation http://www.hemophilia.org 
Regional Centers of Excellence for Biodefense http://www2.niaid.nih.gov/biodefense/research/rce.htm
and Emerging Infectious Diseases
Centers for Disease Control and Prevention http://www.cdc.gov
International
World Federation of Hemophilia http://www.wfh.org
Table 1: Public-health resource organisations
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blood supply was first recognised in 1983, although the
first US case of HIV infection is now known to have
occurred in 1975. By 1985, 74% of patients using factor
VIII were seropositive.68,69 This degree of infection has
had a profound effect on mortality among haemophilic
patients. The median age at death among patients with
haemophilia A decreased from 57 years before the HIV
epidemic to 35 years in 1995, after the epidemic had
grown to enormous proportions. By comparison, the
median lifespan for HIV-negative haemophiliacs was
67 years in 1995.70 Similarly, haemophilic patients
previously have had high rates of infection with HBV
and HCV. Virtually all patients treated with CFC before
1985 were exposed to HCV.71 In one study of HIV-
negative adults, 5% had chronic HBV antigenaemia,
71% were seropositive for HBV, and 82% were
seropositive for HCV.72 25% of the deaths of HIV-
infected patients were from liver disease in 1997 to
1999.73
These observations highlight an important clinical
issue for the treatment of haemophilic patients—that
infections with several viruses complicate and confuse
the clinical picture. For example, among HIV-infected
individuals, subsequent HBV infection produces
chronic disease in about 50% of cases, compared with
10% among HIV-negative patients.74 HIV infection of a
patient chronically infected with HBV, however, results
in a higher degree of HBV replication. Nevertheless,
these patients have milder liver inflammation and less
liver fibrosis than HIV-negative individuals because the
pathogenesis of chronic HBV infection is governed by
immune-mediated mechanisms. Treatment of the
immunodeficiency in these patients can accelerate liver
disease, so antiretroviral therapy in patients infected
with both HIV and HBV should include at least one
agent that is active against HBV.
Similar types of interactions have been observed
between HIV and HCV.75 HIV infection increases the
rate of progression to liver cirrhosis and decreases the
response to interferon-based treatments.76,77 This last
effect has complicated treatment recommendations for
these patients. If the immune system is well preserved
(ie, the CD4-cell count is high), treatment of the HCV
infection first might be prudent. If the patient has more
advanced HIV disease, however, therapy for HIV should
perhaps be started before that for HCV. The effect of
infection with HCV on HIV progression remains
uncertain; however, some studies suggest that patients
infected with both viruses have accelerated progression
of HIV disease and a blunted response to antiretroviral
therapy.
Therapeutic CFC: protection from emerging
infectious agents
Replacement therapy has formed the cornerstone of
haemophilia treatment for longer than 100 years.78 At
first, whole blood was the source of exogenous
coagulation factors. As treatment options evolved, whole
blood was replaced with increasingly purified plasma
product fractions, such as fresh-frozen plasma and
cryoprecipitate, culminating in the high-purity, plasma-
derived and recombinant products available now.
Since the available agents are highly effective, the
choice of coagulation factor is driven primarily by
product safety and cost concerns. Ultimately, cost-
benefit analyses are needed to help physicians treating
haemophilia to choose the best therapeutic option
rationally. There have been no conclusive studies, but
any pharmacoeconomic model will need to include
some key principles. For example, because haemophilic
patients need repeated infusions throughout their lives,
the cumulative risk of transfusion-transmitted infectious
diseases increases over their lifetimes, although
currently the perceived overall threat is low. Further-
more, haemophilic patients are well informed about
their disorder, and they might be expected to demand
safer products when they hear about emerging
infections. Given the complexities associated with choice
of coagulation factor, clinicians and funders must
understand the safety properties of the two main types of
therapeutics, plasma-derived and recombinant
coagulation factors.
Concentrate Producing cell line Factor VIII molecule Addition of human or animal proteins to Virus removal/inactivation method
Cell culture/purification Final formulation
First generation
RecombinateBioclate* CHO Full-length; coexpressed with VWF Yes Yes Immunoaffinity, ion exchange
Kogenate/Helixate* BHK Full-length Yes Yes Immunoaffinity, ion exchange, ultrafiltration
Helixate*
Second generation
ReFacto CHO B-domain deleted Yes No Immunoaffinity, ion exchange, solvent detergent, nanofiltration
Kogenate FS/Helixate FS BHK Full-length Yes No Immunoaffinity, ion exchange, solvent detergent, ultrafiltration
Helixate FS
Third generation
Advate CHO Full-length; coexpressed with VWF No No Immunoaffinity, ion exchange, solvent detergent
ReFacto AF† CHO B-domain deleted No No Immunoaffinity, ion exchange, solvent detergent, nanofiltration
VWF=von Willebrand factor. *No longer commercially available. †Not yet commercially available.
Table 2: Commercial recombinant factor VIII products
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Plasma-derived coagulation factors
Human plasma-derived CFC were one of the original
products used in the treatment of haemophilia. Each
year, tens of thousands of patients receive plasma-derived
products.79 However, for longer than three decades,
plasma-derived CFC have been known to transmit
infectious pathogens.80 Human plasma donations are
therefore routinely screened for known infectious agents
by antigen, antibody, and nucleic-acid testing procedures.
Compared with whole blood or plasma, CFC have the
additional safety advantage of undergoing plasma
fractionation and are subject to procedures to reduce
numbers of viruses during manufacture, including
chromatographic fractionation, nanofiltration, solvent
detergent treatment, and heat inactivation. Thus, plasma-
derived coagulation factors now have a very low risk of
transfusion-mediated infection with HBV, HCV, HIV,
and HTLV I and II. We emphasise, however, that none of
the current viral reduction steps in the manufacture of
concentrates eliminate the risk of transmission of non-
lipid-coated viruses. Plasma-derived CFC have been
widely available for 30 years. They are effective at
preventing and stopping haemorrhage in most patients
with haemophilia and have therefore revolutionised the
lives of patients. Many are able to treat themselves at
home. With regular injections in childhood, most bleeds
can be prevented, allowing children to grow up with
normal joints and not, as was previously commonplace,
crippled with arthritis.
Recombinant coagulation factors
The threat from unknown emerging infectious agents
has encouraged manufacturers to remove dependency on
pooled blood plasma entirely from the manufacturing
process. They have therefore developed methods for
expressing human genes for coagulation factors within
immortalised tissue-culture cells. Subsequent
immunoaffinity and column-chromatographic
purification and viral inactivation and removal steps
result in highly purified therapeutic preparations that are
fully active. These processes decrease the likelihood of
contamination by emerging infectious agents. There is a
possibility, however, that the cell line could be infected
with, and propagate, a pathological prion.81 The first
recombinant factor VIII concentrate was marketed in
1992 for the treatment of haemophilia A. Other products
followed (table 2).
The first-generation recombinant concentrates were
manufactured from cultures that contained animal and
human proteins. Human albumin was also added as an
excipient to the final preparation. In the second
generation, protein stabilisers such as albumin were
replaced with sucrose to eliminate the potential of
pathogen transmission. Recombinant factor VIIa is also a
second-generation product used to treat haemophiliacs
who have antibodies to factor VIII and do not respond to
factor VIII concentrates.
In third-generation concentrates, the factor-VIII-
transfected cell line is grown in medium without addition
of any animal or human proteins.2 This approach has
greatly reduced the risk that could be posed by future
emerging pathogens. The only licensed recombinant
factor IX concentrate, BeneFIX, is also a third-generation
concentrate. To improve safety in the manufacture of
recombinant concentrates, all manufacturing processes
now include a virus-inactivation process, such as solvent
detergent. In addition, the monoclonal antibodies used to
purify factor VIII from cell cultures are made from
hybridoma cell lines grown in the absence of added
mammalian protein. Although recombinant CFC are
judged to be at lower risk of transmitting infectious
agents, concern has been expressed that they might be
associated with a higher incidence of alloantibody
development in response to the transfused factor VIII.82
Future gene-transfer technologies might allow the
preparation of human clotting-factor proteins by novel
and high-yielding processes that would enable the native
protein to be expressed.
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